Dr. Reshma Mahtani, DO
Claim this profileMiami Cancer Institute at Baptist Health
Studies Breast Cancer
Studies Breast cancer
6 reported clinical trials
13 drugs studied
Area of expertise
1Breast Cancer
Stage IV
HER2 negative
ER positive
2Breast Cancer
Stage IV
ER positive
PR positive
Affiliated Hospitals
Clinical Trials Reshma Mahtani, DO is currently running
CDK4/6 Inhibitors
for Metastatic Breast Cancer
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors. Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing).
Recruiting2 awards Phase 33 criteria
Evexomostat + Alpelisib + Fulvestrant
for Breast Cancer
This trial tests a new drug combination for post-menopausal women with a specific type of advanced breast cancer. It aims to see if the new drug can reduce side effects and improve the effectiveness of existing treatments. The treatment works by blocking proteins and hormones that help cancer grow and by managing side effects like high blood sugar.
Recruiting1 award Phase 1 & 211 criteria
More about Reshma Mahtani, DO
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Reshma Mahtani, DO has experience with
- Atezolizumab
- Paclitaxel
- Sacituzumab Govitecan
- Pertuzumab
- Trastuzumab
- Evexomostat
Breakdown of trials Reshma Mahtani, DO has run
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Reshma Mahtani, DO specialize in?
Reshma Mahtani, DO focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Reshma Mahtani, DO currently recruiting for clinical trials?
Yes, Reshma Mahtani, DO is currently recruiting for 4 clinical trials in Miami Florida. If you're interested in participating, you should apply.
Are there any treatments that Reshma Mahtani, DO has studied deeply?
Yes, Reshma Mahtani, DO has studied treatments such as Atezolizumab, Paclitaxel, Sacituzumab govitecan.
What is the best way to schedule an appointment with Reshma Mahtani, DO?
Apply for one of the trials that Reshma Mahtani, DO is conducting.
What is the office address of Reshma Mahtani, DO?
The office of Reshma Mahtani, DO is located at: Miami Cancer Institute at Baptist Health, Miami, Florida 33176 United States. This is the address for their practice at the Miami Cancer Institute at Baptist Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.